Trial Profile
Vemurafenib and ipilimumab in patients with metastatic melanoma.
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.